A randomized Phase II study of vemurafenib plus cobimetinib continuous versus intermittent, in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma.

Grupo Español Multidisciplicinar de Melanoma (GEM)0 个研究点目标入组 116 人开始时间: 2015年1月8日最近更新: 2019年12月10日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 116

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•Disease-Specific Inclusion Criteria:
•1. Patients with histologically confirmed melanoma, either unresectable stage IIIc or stage IV metastatic melanoma.
•2. Patients must be naïve to treatment for locally advanced unresectable or metastatic disease.
•3. Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue.
•4. Measurable disease per RECIST v1.1.
•5. ECOG performance status of 0 or 1.
•6. Additionally, patients to be included in the biomarker sub- study should meet the following criteria:
•- Consent to provide archival tissue for biomarker analyses.
•- Consent to undergo tumor biopsies.
•General Inclusion Criteria:
•7. Male or female patient aged major or equal 18 years.
•8. Able to participate and willing to give written informed.
•9. Life expectancy mayor o igual 12 weeks.
•10. Adequate hematologic and end organ function, within 14 days prior to first dose of study drug treatment:
•- ANC major or equal 1.5 × 109/L.
•- Platelet count major or equal 100 × 109/L.
•- Hemoglobin major or equal 9 g/dL.
•- Albumin major or equal 2.5 g/dL.
•- Bilirubin minor or equal 1.5 × the upper limit of normal (ULN).
•- AST, ALT, and alkaline phosphatase minor or equal 3 × ULN, with the following exceptions:
•- Patients with documented liver metastases: AST and/or ALT minor or equal 5 × ULN.
•- Patients with documented liver or bone metastases alkaline phosphatase minor o equal 5 × ULN.
•- Serum creatinina minor o equal 1.5 × ULN or CrCl major or equal 40 mL/min on the basis of measured CrCl from a 24- hour urine collection.
•11. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use 2 effective forms of contraception during the course of this study and for at least 6 months after completion of study therapy.
•12. Negative serum pregnancy test within 10 days prior to commencement of dosing in women of childbearing potential.
•13. Absence of any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the study protocol and follow-up after treatment discontinuation schedule.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 116
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 116

排除标准

•Cancer-Related Exclusion Criteria:
•1. History of prior RAF or MEK pathway inhibitor treatment.
•2. Palliative radiotherapy within 14 days prior to the first dose of study treatment.
•3. Major surgery or traumatic injury within 14 days prior to first dose of study treatment.
•4. Active malignancy other than melanoma that could potentially interfere with the interpretation of efficacy measures. Patients with a previous malignancy within the past 3 years are excluded except for patients with resected BCC or SCC of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast.
•5. History of isolated elevation in prostate-specific antigen in the absence of radiographic evidence of metastatic prostate cancer is allowed.
•Exclusion Criteria Based on Organ Function Ocular:
•6. History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration.
•7. The risk factors for RVO are listed below. Patients will be excluded if they have the following conditions:
•- Uncontrolled glaucoma with intra-ocular pressures > 21 mmHg.
•- Serum cholesterol major or equal Grade 2.
•- Hypertriglyceridemia major or equal Grade 2.
•- Hyperglycemia (fasting) major or equal Grade 2.
•8. History of clinically significant cardiac dysfunction, including the following:
•- Current unstable angina.
•- Symptomatic congestive heart failure of New York
•Heart Association class 2 or higher.
•- History of congenital long QT syndrome or mean (average of triplicate measurements) QTcF > 450 msec at baseline or uncorrectable abnormalities
•in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus).
•- Uncontrolled hypertension major or equal Grade 2 (patients with a history hypertension controlled with anti- hypertensives to minor or equal Grade 1 are eligible).
•- Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%.
•Central Nervous System:
•9. Patients with active CNS lesions (including carcinomatous meningitis) are excluded. However, patients are eligible if:
•- All known CNS lesions have been treated with stereotactic therapy or surgery, AND
•- There has been no evidence of clinical and radiographic disease progression in the CNS for major or equal 3 weeks after radiotherapy or surgery.
•Whole brain radiotherapy is not allowed, with the exception of patients who have had definitive resection or stereotactic therapy of all radiologically detectable parenchymal brain lesions.
•General Exclusion Criteria:
•10. Current severe, uncontrolled systemic disease.
•11. History of malabsorption or other condition that would interfere with absorption of study drugs.
•12. Pregnant or lactating.
•13. Unwillingness or inability to comply with study and follow- up procedures.
•14. The following foods/supplements are prohibited at least 7 days prior to in

研究者

发起方

Grupo Español Multidisciplicinar de Melanoma (GEM)

相似试验

进行中（未招募）

1 期

Evaluate the safety and the efficacy of Vemurafenib/PEG-interferon in melanoma patientsEvaluate the safety and the efficacy of Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment in advanced melanoma patients harboring the V600BRAF mutationMedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864

EUCTR2013-003730-33-ITFondazione Melanoma ONLUS48

进行中（未招募）

1 期

A phase II trial of vemurafenib plus cobimetinib in patients treated with prior first-line systemic immunotherapy for inoperable locally advanced or metastatic melanomaPatients with advanced melanoma who have received one prior immunotherapy systemic regimen for advanced disease, for whom vemurafenib/cobimetinib treatment has been scheduled by the treating physician.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864

EUCTR2017-000504-20-ITFONDAZIONE MELANOMA ONLUS62

进行中（未招募）

1 期

An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancersPatients with cancers (excluding melanoma and papillary thyroidcancer) harboring BRAF V600 mutations as identified by theroutinely performed mutation analysis assays at each individualparticipating siteMedDRA version: 17.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-004426-10-DEF. Hoffman-La Roche Ltd.500

进行中（未招募）

1 期

EUCTR2011-004426-10-ESF. Hoffman-La Roche Ltd.121

进行中（未招募）

1 期

An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancersPatients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual participating siteMedDRA version: 18.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10008593 Term: Cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 1

EUCTR2011-004426-10-GBF. Hoffman-La Roche Ltd.208